05/02/2013 19:11:00

Goldman's Jim O'Neill, Chairman of Asset Management, to Retire -Memo

Related content

By Liz Moyer

Goldman Sachs Group Inc.'s (GS) influential market strategist Jim O'Neill will retire from the firm later this year, according to a Goldman memo.

Mr. O'Neill has been chairman of Goldman Sachs Asset Management since September 2010. He joined Goldman as a partner in 1995 from Swiss Bank Corp., where he had been global head of research. He hasn't announced his next move.

A memorandum to employees on Tuesday signed by Goldman Chairman and Chief Executive Officer Lloyd Blankfein and President and Chief Operating Officer Gary Cohn credited Mr. O'Neill with coining the term BRICs, an acronym for the fast-growing economies of Brazil, Russia, India and China. He is also the author of a book, "The Growth Map," published in 2011.

"Jim's BRIC thesis has challenged conventional thinking about emerging markets and, as a result, has had a significant economic and social impact," Mr. Blankfein and Mr. Cohn said in the memo.

Mr. O'Neill is the latest partner to depart Goldman. Last month, David Viniar, the firm's chief financial officer since its initial public offering, retired and was succeeded by Harvey Schwartz. Goldman hasn't named a new chairman for its asset management division.

Write to Liz Moyer at liz.moyer@dowjones.com

(END) Dow Jones Newswires

February 05, 2013 14:11 ET (19:11 GMT)

Copyright (c) 2013 Dow Jones & Company, Inc.

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
Ingen indlæg

Regulatory news

Tech Companies Send Criticism Along With NSA-Related Data -- Update

04/02/2014 00:06:00
By Danny Yadron Technology companies including Google Inc. and Microsoft Corp. released new figures on the amount of data requests they received from U.S. ..

U.S. Hot Stocks: Hot Stocks to Watch

03/02/2014 14:07:00
Among the companies with shares expected to actively trade in Monday's session is Herbalife Ltd. (HLF). Herbalife Ltd. (HLF) raised its fourth-quarter outl..

Pfizer Study Meets Primary Endpoints

03/02/2014 13:05:00
Pfizer Inc. (PFE) said Monday that a Phase 2 trial of its advanced breast cancer treatment met its primary endpoint. Pfizer said a study comparing the effec..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
Cliffs Natural Resources Inc. Reports Continued Capital Spending Reduction and Cost Improvements in Its Second-Quarter 2014 Results
2
Zacks Small-Cap Research Updates Coverage on Northstar Healthcare (TSX:NHC) with an Outperform Rating - Video Research Alert on InvestmentPitch.com
3
ASM INTERNATIONAL N.V. REPORTS SECOND QUARTER 2014 RESULTS
4
ADVA Optical Networking Reports Q2 2014 Financial Results In Line with Guidance
5
Bombardier Announces New Organizational Structure

Related stock quotes

Goldman Sachs Group Inc 176.62 -0.1% Stock price decreasing

Buy and sell signals

  • Trend
  • Moneymachine

Related companies
Get access to information and recommendations of related companies with our PLUS package.

You get access to 7 valuable investment tools.

Click here to read more about the PLUS package.
Euroinvestor around the globe: Euroinvestor.dk | Euroinvestor.se | Euroinvestor.no | Euroinvestor.fr | Forexinvestor.com| Wisselkoersen.nl | Valuta.se | Valutaveksel.no | Divisas.es | Valute.it
Copyright Euroinvestor A/S 2014   Disclaimer and Terms of Use
Quote information is delivered by Interactive Data.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
24 July 2014 17:44:29
(UTC) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20140723.1 - EUROWEB6 - 2014-07-24 18:44:29 - 2014-07-24 17:44:29 - 1000 - Website: OKAY